Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
46.92
-0.09 (-0.19%)
Official Closing Price
Updated: 5:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
75
76
Next >
Price Over Earnings Overview: Bristol-Myers Squibb
Today 10:00 EDT
Via
Benzinga
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
July 03, 2025
Via
Benzinga
Is Pfizer Stock a Yield Trap?
July 03, 2025
Via
The Motley Fool
Topics
Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
July 02, 2025
Via
Benzinga
3 Large-Cap Stocks Skating on Thin Ice
July 02, 2025
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...
Via
StockStory
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
June 30, 2025
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
Via
Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
June 28, 2025
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors.
Via
Chartmill
FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers
June 27, 2025
FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements.
Via
Benzinga
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
June 26, 2025
From
Bristol Myers Squibb
Via
Business Wire
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
June 26, 2025
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Via
Investor's Business Daily
Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drug
June 25, 2025
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.
Via
Benzinga
Topics
Fraud
Lawsuit
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Stock Worth Considering
June 23, 2025
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers strong profitability, a high dividend yield, and an attractive valuation, making it a potential pick for value investors.
Via
Chartmill
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
June 18, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks
June 18, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Bristol Myers Squibb Announces Dividend
June 17, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers’ Cancer Drug Data Fuels Retail Buzz, But Bearish Sentiment Lingers
June 16, 2025
The new data showed that its lymphoma therapy, Breyanzi, delivered a 95.5% response rate and strong 24-month survival outcomes in a Phase 2 trial.
Via
Stocktwits
Top S&P500 movers in Monday's session
June 16, 2025
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via
Chartmill
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
June 16, 2025
From
Bristol Myers Squibb
Via
Business Wire
2 Beaten-Down Dividend Stocks to Buy Right Now
June 16, 2025
Via
The Motley Fool
Topics
Economy
World Trade
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
June 12, 2025
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.
Via
Benzinga
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
June 12, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
June 12, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
June 11, 2025
From
Bristol Myers Squibb
Via
Business Wire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus
June 10, 2025
From
Philogen S.p.A.
Via
GlobeNewswire
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
June 08, 2025
Via
The Motley Fool
Topics
Intellectual Property
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock Worth Considering
June 06, 2025
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.18% dividend yield with strong profitability and reasonable valuation, making it a compelling choice for dividend investors.
Via
Chartmill
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
June 05, 2025
Via
The Motley Fool
Topics
Intellectual Property
Retirement
1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About
June 05, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
June 04, 2025
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
75
76
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.